Eflornithine (Vaniqa) is commonly used to treat hirsutism in patients with PCOS.

Eflornithine in a recent study was found to significantly improve beta cell function in type 1 diabetes.

Emily K. Sims, a pediatric endocrinologist, highlights the potential for improving the quality of life in type 1 diabetes by enhancing endogenous insulin secretion through long-term combination therapy [Ref].

The study investigates DFMO, known for inhibiting the polyamine biosynthesis pathway, involved in inflammatory responses in autoimmune diseases like type 1 diabetes.

DFMO, used for African sleeping sickness and unwanted hair growth, is being explored for its impact on beta-cell function in a safety study with 41 recently diagnosed type 1 diabetes subjects, indicating a novel approach beyond current treatments.

Teplizumab, JAK Inhibitors, Immunotherapy, and now Vaniqa are some drugs being tested for the the treatment of Type 1 Diabetes. 

These drugs act by preserving beta cell function and enhance insulin  secretion.